Cell Penetrating Peptides (CPPs) are considered as a powerful tool for medical applications. However, there are still no FDA approved CPP-conjugated drugs and several clinical trials have been discontinued. Non-tissue specific CPP-conjugated drugs have been a major hurdle in designing therapies with desired efficacy and acceptable toxicity.

Cell Penetrating Peptides (CPPs) are considered as a powerful tool for medical applications. However, there are still no FDA approved CPP-conjugated drugs and several clinical trials have been discontinued. Non-tissue specific CPP-conjugated drugs have been a major hurdle in designing therapies with desired efficacy and acceptable toxicity.